NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired bluebird bio, Inc. ("Blue" or the "Company") (NASDAQ:BLUE) securities during the period of April 24, 2023 through December 8, 2023, inclusive ("the Class Period"). Investors have until May 28, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
[Click here to learn more about the class action]
On December 8, 2023, Blue announced that the United States Food and Drug Administration (FDA) approved its drug Lyfgenia, also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events. However, the Lyfgenia approval came ...
BLUE) Investors>Full story available on Benzinga.com